Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 7/20 | 0.38 |
| ▸ | CKS1B | P61024 | 5/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 5/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 2/20 | 0.32 |
| ▸ | CCR8 | P51685 | 2/20 | 0.32 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16582578 | 0.90 | KDM4E (0.33) | — | |
| SCHEMBL19859928 | 0.85 | TOP1 (0.38) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL16582584 | 0.84 | CCR1 (0.37) | CCR1CCR8CCR5COMT | |
| SCHEMBL16582561 | 0.77 | ESR1 (0.36) | PIK3CD | |
| SCHEMBL16582581 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL16582889 | 0.72 | NCOA3 (0.36) | — | |
| SCHEMBL16582577 | 0.72 | KMT2A (0.38) | — | |
| SCHEMBL16582562 | 0.72 | CCR1 (0.31) | CCR1CCR8CCR5 | |
| SCHEMBL16582615 | 0.72 | NR1H2 (0.30) | — | |
| SCHEMBL16582560 | 0.72 | NR1H2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9893299-B2 | Heterocyclic compounds | MERCK PATENT GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9893299-B2 | Heterocyclic compounds | MERCK PATENT GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20160226003-A1 | HETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20160226003-A1 | HETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| WO-2015036078-A1 | HETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160226003-A1 | HETEROCYCLIC COMPOUNDS | ERCC1, VDAC2, NES | TOP1 2451/4885CKS1B 3902/4885SKP2 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.